19. Enterprise-wide Disclosures

Geographic Area Information

Revenues, including license fees, royalties, grant income, and other revenues by geographic area are based on the country of domicile of the licensee or grantor.

Geographic Area	Revenues for the Year ending December 31,
	2013		2012		2011
Domestic	$	2,106,161	$	2,529,669	$	3,059,810
Asia		2,328,175		1,385,658		1,374,349
Total revenues	$	4,434,336	$	3,915,327	$	4,434,159

Major Sources of Revenues

BioTime has two major customers and two major grants comprising significant amounts of total revenues.

All of BioTime’s royalty revenues were generated through sales of Hextend^® by Hospira in the U.S. and by CJ in the Republic of Korea. BioTime also earned license fees from CJ and Summit.

BioTime was awarded a $4,721,706 grant for a stem cell research project related to its PureStem^™ technology by CIRM in April 2009. The CIRM grant covered the period of September 1, 2009 through August 31, 2012. BioTime recognized $0 and $1,047,106 as revenues as of December 31, 2013 and December 31, 2012, respectively. The final quarterly installment of $392,664 was collected in February 2013.

During 2013, BioTime received $111,691 and recognized as revenues $150,239 of a $335,900 grant awarded by the National Institutes of Health (“NIH”). During 2012, BioTime received $45,645 and recognized as revenues $47,507. The grant period commenced on September 30, 2011 and will end on September 29, 2014. As of December 31, 2013, $110,237 remained available for funding under the grant.

During 2013, grant income also included awards from a separate grant awarded by the NIH in 2013 in the amount of $71,355, and grants from other sources in the amount of $1,333,901 recognized through Cell Cure Neurosciences, $13,838 through Life Map Sciences, Ltd., and $3,996 through ES Cell International. During 2012, grant income also included $1,109,699 recognized through Cell Cure Neurosciences and $18,145 through Life Map Sciences, Ltd.

During 2013, BioTime received $1,082,077 and recognized $609,314 (net of $707,695 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences. During 2012, BioTime received $1,222,516 and recognized $373,798 (net of $379,098 in royalty and commission fees) in net subscription and advertisement revenues through LifeMap Sciences.

The following table shows the relative portions of BioTime’s royalty and license fee revenues paid by Hospira, CJ, and Summit that were recognized during the years ended December 31, 2013, 2012, and 2011, subscription and advertisement revenues, and grant income recognized during the same periods with respect to grants provided by the office of the Chief of Scientist of Israel (“OCS”), the NIH (SBIR) and CIRM:

Sources of Revenues	% of Total Revenues for Year ended December 31,
	2013			2012			2011
Hospira		6.5	%		11.0	%		14.2	%
CJ		1.7	%		2.9	%		3.5	%
Summit		20.3	%		3.7	%		3.3	%
CIRM		0.0	%		26.7	%		35.4	%
NIH		5.0	%		1.2	%		0.6	%
OCS		27.9	%		26.0	%		23.0	%
Subscription and Advertising (various customers)		38.6	%		28.5	%		20.0	%